0000000000331389

AUTHOR

Thomas M. Gress

showing 2 related works from this author

StellaTUM: current consensus and discussion on pancreatic stellate cell research

2011

The field of pancreatic stellate cell (PSC) biology is very young, as the essential in-vitro tools to study these cells (ie, methods to isolate and culture PSC) were only developed as recently as in 1998. Nonetheless, there has been an exponential increase in research output in this field over the past decade, with numerous research groups around the world focusing their energies into elucidating the biology and function of these cells. It is now well established that PSC are responsible for producing the stromal reaction (fibrosis) of two major diseases of the pancreas—chronic pancreatitis and pancreatic cancer. Despite exponentially increasing data, the methods for studying PSC remain var…

Liver CirrhosisPathologycell migrationpancreatic cancerCellpancreatitisPancreatic stellate cellLeading Articlehepatic surgerycell biologymolecular biologyhepatic fibrosis1506pancreaspancreatic surgerysignallinghepatic stellate cellalcoholPancreatic Stellate CellsGastroenterologypancreatic functionddc:medicine.anatomical_structurePancreaspancreatic fibrosissignal transductionstellate cellsmedicine.medical_specialtyStromal cellacute pancreatitisextracellular matrixadjuvant treatmentAbdominal surgerycancer geneticsliverpancreatic enzymesdigestive systemchronic pancreatitisstem cellsPancreatitis ChronicPancreatic cancermedicinecancerHumansRegenerationpancreatic physiologyendoscopyProgenitor cellmarkeradenocarcinomaHelicobacter pyloribusiness.industryfibrosisPancreatic Diseasesmedicine.diseaseexperimental pancreatitisLiver RegenerationPancreatic Neoplasmspancreatic pathologyconsensusCancer cellgene expressionHepatic stellate cellbusinesspancreatic diseaseGut
researchProduct

Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?

2021

Gastroenteropancreatic neuroendocrine neoplasia (GEPNEN) comprises clinically as well as prognostically diverse tumour entities often diagnosed at late stage. Current classification provides a uniform terminology and a Ki67-based grading system, thereby facilitating management. Advances in the study of genomic and epigenetic landscapes have amplified knowledge of tumour biology and enhanced identification of prognostic and potentially predictive treatment subgroups. Translation of this genomic and mechanistic biology into advanced GEPNEN management is limited. ‘Targeted’ treatments such as somatostatin analogues, peptide receptor radiotherapy, tyrosine kinase inhibitors and mammalian target…

0301 basic medicinemedicine.medical_treatmentcancer geneticsNeuroendocrine tumorsBioinformaticschemotherapyMolecular oncologyEpigenesis Genetic03 medical and health sciences0302 clinical medicinemolecular oncologyStomach NeoplasmsIntestinal NeoplasmsBiomarkers TumormedicineHumanscancer genetics; chemotherapy; immunotherapy; molecular oncology; neuroendocrine tumorsEpigeneticsPrecision Medicine610 Medicine & healthbusiness.industryGastroenterologyImmunotherapymedicine.diseasePancreatic NeoplasmsRadiation therapyClinical trial030104 developmental biologyTargeted drug delivery030220 oncology & carcinogenesis570 Life sciences; biologyIdentification (biology)immunotherapyneuroendocrine tumorsbusiness
researchProduct